Literature DB >> 35213389

Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010).

Cole D Stang1, Aidan F Mullan2, Emanuele Camerucci1, Mania Hajeb1, Pierpaolo Turcano3, Peter Martin2, Michelle M Mielke2, Keith A Josephs1, Matthew Splett4, Victor Abler4, Bradley F Boeve1, James H Bower1, Rodolfo Savica1,2.   

Abstract

BACKGROUND: Parkinson's disease (PD)-associated psychosis is a well-known non-motor complication, occurring years after diagnosis of PD. Incidence data vary across different studies highlighting a need for long-term observation and clinical definition.
OBJECTIVE: To determine the incidence of psychosis in patients with PD and to investigate their survival in an incident cohort study from 1991-2010 in Olmsted County, MN.
METHODS: We used the Rochester Epidemiology Project to define an incident-cohort study of parkinsonism (1991-2010) in Olmsted County, MN. A movement-disorder specialist reviewed the electronic medical records and applied diagnosis criteria to PD. Psychosis was diagnosed using of NINDS/NIMH unified criteria.
RESULTS: We identified 669 cases of parkinsonism; 297 patients were clinically diagnosed with PD. 114/297 (38.4%) patients had evidence of psychosis (60% male); the median onset age of psychosis was 79.4 years. The incidence of Parkinson's disease psychosis (PDP) was 4.28/100 person-years. PDP patients had a 71% increased risk of death compared to PD patients. In PD patients without psychosis, men had 73.4% increased risk of death compared to women, whereas no significant sex difference was observed among PDP men vs. women. Of 114 patients diagnosed with psychosis, 59 were treated with antipsychotics. There was no significant difference in survival between treated and untreated patients.
CONCLUSION: PDP increased the odds of death compared to PD patients. Men with PD without psychosis had greater odds of death compared to women; however, in PD with psychosis the odds of death were comparable among sexes. Lastly, treatment with anti-psychotics did not significantly affect survival.

Entities:  

Keywords:  Parkinsonism; antipsychotics; delirium; hallucinations; psychosis

Mesh:

Year:  2022        PMID: 35213389      PMCID: PMC9336204          DOI: 10.3233/JPD-213035

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.520


  37 in total

1.  Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group.

Authors:  J Jankovic; M McDermott; J Carter; S Gauthier; C Goetz; L Golbe; S Huber; W Koller; C Olanow; I Shoulson
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

2.  The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

Authors:  Gilles Fénelon; Thierry Soulas; Franck Zenasni; Laurent Cleret de Langavant
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

3.  Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

Authors:  Joel Mack; Peter Rabins; Karen Anderson; Susanne Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Gregory Pontone; Howard Weiss; James R Williams; Laura Marsh
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

4.  Progression of motor impairment and disability in Parkinson disease: a population-based study.

Authors:  Guido Alves; Tore Wentzel-Larsen; Dag Aarsland; Jan Petter Larsen
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

5.  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

6.  How common are complications of Parkinson's disease?

Authors:  Anette Schrag; Yoav Ben-Shlomo; Niall Quinn
Journal:  J Neurol       Date:  2002-04       Impact factor: 4.849

7.  Association between family history of dementia and hallucinations in Parkinson disease.

Authors:  Diana Paleacu; Edna Schechtman; Rivka Inzelberg
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

Review 8.  Sex differences in movement disorders.

Authors:  Sara Meoni; Antonella Macerollo; Elena Moro
Journal:  Nat Rev Neurol       Date:  2020-01-03       Impact factor: 42.937

Review 9.  Psychosis in Parkinson's Disease.

Authors:  Dominic H Ffytche; Dag Aarsland
Journal:  Int Rev Neurobiol       Date:  2017-06-16       Impact factor: 3.230

10.  A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Michael Samuel; Chris Fox; Anthony S David
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.